Navigation Links
In blood vessel stents, innovative materials allow better control, delivery of gene therapy

Before gene therapy becomes practical for treating human diseases, researchers must master the details of safe and effective delivery. Cardiology researchers at The Childrens Hospital of Philadelphia have advanced delivery techniques by creating a versatile synthetic material that can bind to a variety of gene therapy vectors and can be custom-designed for controlled local release of therapeutic genes at a disease site.

In an animal study, the research team used their new synthetic formulation to bind adenoviruses to bare metal stents, tiny metal scaffolds inside the carotid arteries of rats. Adenovirus served as a gene therapy vector to carry genes for an enzyme that significantly reduced restenosis, the hazardous narrowing of a blood vessel that often occurs despite the presence of a stent designed to hold it open.

Although the materials are in an early stage, the hope is that this method may help to treat artery disease in people. We developed a synthetic gene delivery system that can be used for any gene therapy vector, not just adenoviruses, said study leader Robert J. Levy, M.D., the William J. Rashkind Chair of Pediatric Cardiology at The Childrens Hospital of Philadelphia. Furthermore, this new formulation allows us to increase the dosage of gene therapy vectors delivered, and we can tune the materials for sustained release over a longer time period.

Levys group reported its study this week in the online version of the journal Circulation, published by the American Heart Association.

Over the past decade, stents have become increasingly useful in treating constricted blood vessels in heart disease and in peripheral artery disease. Stents, which expand partially blocked blood vessels to improve circulation, may be made of bare metal or may have a coating of polymers that release drugs.

Neither type is ideal. Polymer coatings cause inflammation in vessels, which may lead to new bottlenecks at the same time the coating releases drugs meant to reduce vessel injury. Bare metal stents produce less inflammation, but without the benefit of drug delivery. Previously, in a proof-of-principle study in animals, Levys group attached to stents an extremely thin layer of protein, one molecule thick, containing adenovirus vectors that delivered genes that successfully inhibited restenosis. However, that method had serious limitations; it operated only within a narrow range of temperatures and acidity levels, and was useable only with adenovirus vectors.

The new formulation, said Levy, is more robust, more controllable and adaptable to any virus used as a gene therapy vector, not just adenoviruses. His team synthesized three components into a complex that tethers viral vectors to stent surfaces. One of the three components is an amplifier that increases the dose of gene vector more than fourfold over the previous formulation.

In addition, by varying another component, the stent can be tuned to release vector at a controlled rate that can theoretically be tailored to a schedule appropriate for the particular treatment. Prior studies have shown that 90 percent of the gene vector is released within 12 to 24 hours, after which vessel blockages regrow, said Levy. In this study, the stents had significant coverage of the vector seven days laterand less restenosis. Our goal is to customize the materials to allow peak release of the vector when it can have the maximum benefit.

The adenovirus vector carries genes that code for inducible nitric oxide synthase (iNOS), a protein that controls cell damage in blood vessels. In the current study, the iNOS reduced restenosis by 56 percent in the carotid arteries of treated rats, as compared with control animals.

Although this particular study used adenovirus vectors, said Levy, the synthetic formulation could tether any other type of viral gene therapy vector to the metal stents. It might also carry other therapeutic agents in addition to gene vectors. Further studies, he added, will refine these methods and investigate them in larger animal models that more closely simulate human vessel disease.


Contact: John Ascenzi
Children's Hospital of Philadelphia

Related medicine news :

1. Mediware Introduces Comprehensive Vision for Blood Center Technology
2. High Blood Pressure May Be Buffer Against Headaches
3. Potential blood test for chronic sinusitis identified
4. Blood pressure drugs halt pancreatic cancer cell growth, Jefferson researchers find
5. Abbott FreeStyle Freedom(R) Lite Blood Glucose Monitoring System Now Available With No Coding for People With Diabetes
6. PATHFAST(R): Rapid Whole Blood Immunoassay Analyzer from Polymedco
7. Blood vessels: The pied piper for growing nerve cells
8. Cholesterol, blood pressure control may reverse atherosclerosis in adults with diabetes
9. Aggressive Cholesterol, Blood Pressure Treatment Shows Some Benefit
10. Microwave treatments for enlarged prostate cause blood pressure surges
11. Blood pressure enzyme can have tumor-sensing role
Post Your Comments:
(Date:10/13/2015)... ... 13, 2015 , ... The added calories and sugar in an average trick-or-treat ... a parent to do? Registered dietitians from Retrofit , the leading corporate weight ... year. , “Halloween is a high-calorie holiday,” said Dara Aronow, Registered Dietitian, Retrofit. ...
(Date:10/13/2015)... ... 2015 , ... Vision Group Holdings, the largest LASIK provider in North America, ... The LASIK Vision Institute and TLC Laser Eye Centers, Vision Group Holdings has performed ... correction. , Global Laser Vision will continue to operate in San Diego as it ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... the United States, today announced the release of its limited edition holiday seasonal ... Cocktail Agua Fresca. All feature the unique flavor combinations and delicious taste Califia ...
(Date:10/13/2015)... ... 13, 2015 , ... ProText Kinetic Panel is a typography creation tool made ... can create energetic text animations in any layout without the use of keyframes. Using ... timeline and stylize the text. With intuitive on-screen controls, users can re-position and scale ...
(Date:10/13/2015)... Williamsport, PA (PRWEB) , ... October 13, 2015 , ... ... (SH) 2015 utility costs were 36 percent lower per square foot than in 2009. ... the actual cost of heating and cooling has decreased by eight percent. , ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... , Oct. 13, 2015  The spine division ... leader in musculoskeletal healthcare, will showcase its portfolio of ... Spine Society (NASS) annual meeting, October 14-17, 2015, in ... also host two clinical events: "Supplemental MIS ... Presentation Wednesday, October 14 12:30 – 1 p.m. ...
(Date:10/13/2015)... N.J. , Oct. 13, 2015  ContraVir ... the "Company"), a biopharmaceutical company focused on the ... announced the closing of its previously announced underwritten ... stock and warrants to purchase up to 3,000,000 ... fixed combined price to the public of $3.00. ...
(Date:10/13/2015)... JOLLA, Calif. , Oct. 13, 2015  Human ... revolutionize the practice of medicine, announced today the launch ... clinical research project that has the potential to transform ... San Diego, CA , at HLI,s headquarters ... in 2016 in other US and International cities. ...
Breaking Medicine Technology: